Network pharmacology in drug repositioning of Chinese medicines: application status and thinking_Chinese Journal of Evidence-Based Medicine

Authors：

LIU Yanfei ^1,2 , SUN Mingyue ² , ZHAO Yingke ³ , YAO Hezhi ² ,  LIU Yue ⁴ ,  GAO Rui ²

1. Graduate School of Beijing University of Chinese Medicine, Beijing, 100029, P.R.China;
2. Institute of Clinical Pharmacology of Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, P.R.China;
3. School of Chinese Medicine, the University of Hong Kong, Hong Kong, 999077, P.R.China;
4. Cardiovascular Diseases Center, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, 100091, P.R.China;

Corresponding author：

LIU Yue, Email: liuyueheart@hotmail.com; GAO Rui, Email: ruigao@126.com

Keywords：

Drug repositioning; Chinese medicinals; Network pharmacology; Conventional drug in new use

DOI：

10.7507/1672-2531.201707013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Drug repositioning, also known as conventional drug in novel use, is the discovery of new indications or novel use of the drug. It has received more and more attention not only in the research and development of western medicine, but also gradually become popular in the research field of Chinese medicine. The new phase of drug repositioning research is based on computer technology, and its research methods and techniques keep up with the time. Network pharmacology is playing more and more important role in the study of drug repositioning. At present, the strategies used in the study of traditional Chinese medicine repositioning include small molecules (or ligands), drug targets and network theory. In this paper, the concept, research status, application status of Chinese medicinals repositioning and application status and strategy of network pharmacology are reviewed, in order to provide references for the study of drug repositioning in Chinese medicinal.

Citation： LIU Yanfei, SUN Mingyue, ZHAO Yingke, YAO Hezhi, LIU Yue, GAO Rui. Network pharmacology in drug repositioning of Chinese medicines: application status and thinking. Chinese Journal of Evidence-Based Medicine, 2017, 17(11): 1344-1349. doi: 10.7507/1672-2531.201707013 Copy

1.	Chong CR, Sullivan DJ. New uses for old drugs. Nature, 2007, 448(7154): 645-646.
2.	Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ, 2003, 22(2): 151-185.
3.	Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol, 2014, 32(1): 40-51.
4.	盛苗苗, 蒋澄宇. 精确医学为老药新用及联合用药带来新契机. 生命科学, 2015, 27(3): 322-326.
5.	Ekins S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res, 2011, 28(8): 1785-1791.
6.	Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat product, 2012, 75(3): 311-335.
7.	Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod, 2014, 77(3): 703-723.
8.	Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science, 2009, 325(5937): 161-165.
9.	Sun Y, Liu Y, Chen K. Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives. Sci China Life Sci, 2016, 59(3): 292-298.
10.	Smith I, Williamson EM, Putnam S, et al. Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr Rev, 2014, 72(5): 319-333.
11.	Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database Syst Rev, 2010, (12): CD007769.
12.	Yang Z, Zhao T, Liu H, et al. Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep, 2016, 6: 19383.
13.	Tian L, Shen D, Li X, et al. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget, 2016, 7(2): 1619.
14.	Guo M, Liu Y, Shi D. Cardiovascular actions and therapeutic potential of tetramethylpyrazine (active component isolated from rhizoma chuanxiong): roles and mechanisms. Biomed Res Int, 2016, 2016: 2430329.
15.	Hui L, Xue YA, Wei SH, et al. Protective effects of tetramethylpyrazine on cerebrovascular regulations in rats with chronic alcoholic encephalopathy. Biomed Environ Sci, 2015, 28(9): 691-695.
16.	Kong X, Zhong M, Su X, et al. Tetramethylpyrazine promotes migration of neural precursor cells via activating the phosphatidylinositol 3-kinase pathway. Mol Neurobiol, 2016, 53(9): 6526-6539.
17.	Wang C, Wang P, Zeng W, et al. Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway. Bioorg Med Chem Lett, 2016, 26(4): 1287-1291.
18.	Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008, 8(2): 99-111.
19.	Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6(2): e16556.
20.	Tillhon M, Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol, 2012, 84(10): 1260-1267.
21.	Mahmood K, Zia KM, Zuber M. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: a review. Int J Biol Macromol, 2015, 81: 877-890.
22.	Seo HJ, Wang SM, Han C, et al. Curcumin as a putative antidepressant. Expert Rev Neurother, 2015, 15(3): 269-280.
23.	Kaufmann FN, Gazal M, Bastos CR, et al. Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol, 2016, 784: 192-198.
24.	Al-Karawi D, Mamoori A, Alem D, et al. The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother Res, 2016, 30(2): 175-183.
25.	Ho WE, Peh HY, Chan TK, et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther, 2014, 142(1): 126-139.
26.	Jin O, Zhang H, Gu Z, et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol, 2009, 6(6): 461.
27.	Li J, Casteels T, Frogne T, et al. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell, 2017, 168(1-2): 86-100, 115.
28.	Liu J, Lee J, Salazar HMA, et al. Treatment of obesity with celastrol. Cell, 2015, 161(5): 999-1011.
29.	信琪琪, 刘玥, 杨琳, 等. 中药银杏制剂与糖尿病治疗: 作用机制与临床应用. 中国中药杂志, 2014, 39(23): 4509-4515.
30.	Zhi Y, Pan JH, Shen WH, et al. Ginkgolide B inhibits human bladder cancer cell migration and invasion through MicroRNA-223-3p. Cell Physiol Biochem, 2016, 39(5): 1787-1794.
31.	Xu K, Wang P, Xu X, et al. An overview on structural modifications of ligustrazine and biological evaluation of its synthetic derivatives. Res Chem Intermediat, 2015, 41(3): 1385-1411.
32.	刘瑞武, 尹大力, 郭积玉. 10 位结构修饰 14β-侧链紫杉醇衍生物的合成及其抗肿瘤活性. 中国药物化学杂志, 2000, 10(1): 18-25.
33.	Li Q, Wang Y, Feng N, et al. Novel polymeric nanoparticles containing Tanshinone IIA for the treatment of hepatoma. J Drug Target, 2008, 16(10): 725-732.
34.	任瑾, 杜倩, 艾凤伟, 等. 药物新剂型与新技术在中药制剂中的应用开发. 中成药, 2015, 37(2): 392-396.
35.	Li S. Farmework and practice of network based studies for Chinese herbal formula. J Chin Integr Med, 2007, 5(5): 489-493.
36.	Hopkins AL. Network pharmacology. Nat Biotechnol, 2007, 25(10): 1110-1111.
37.	Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 4(11): 682-690.
38.	张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展. 中国药理学与毒理学杂志, 2015, 29(6): 883-892.
39.	张永祥, 程肖蕊, 周文霞. 药物重定位—网络药理学的重要应用领域. 中国药理学与毒理学杂志, 2012, 26(6): 779-786.
40.	Yang H, Shen Y, Chen J, et al. Structure-based virtual screening for identification of novel 11β-HSD1 inhibitors. Eur J Med Chem, 2009, 44(3): 1167.
41.	梁英喜, 贺昱甦, 蒋芦荻, 等. 利用重定位策略从中药中发现 L-型钙离子通道作用降压药. 中国中药杂志, 2015, 40(18): 2650-2654.
42.	杨珍, 张燕玲, 乔延江. ETB 受体拮抗剂三维药效团的构建. 世界科学技术-中医药现代化, 2014, 14(4): 1786-1792.
43.	吴纯伟, 路丽, 梁生旺, 等. 药物靶标预测技术在中药网络药理学中的应用. 中国中药杂志, 2016, 41(3): 377-382.
44.	Liang XJ, Li HY, Li S. A novel network pharmacology approach to analyse traditional: herbal formulae: the liu-wei-di-huang pill as a case study. Mol Bio Syst, 2014, 10(5): 943-1212.
45.	Li HY, Zhao LH, Zhang B, et al. A network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes. Evid Based Complement Alternat Med, 2014, 2014: 495840.
46.	Liu HP, Zeng LT, Yang KL, et al. A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility. Evid Based Complement Alternat Med, 2016, 2016: 2960372.
47.	李翔, 吴磊宏, 范骁辉, 等. 复方丹参方主要活性成分网络药理学研究. 中国中药杂志, 2011, 36(21): 2912-2915.
48.	Nielsen SK, Ursu O, Yang JJ, et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inform, 2011, 30(2-3): 100-111.

1. Chong CR, Sullivan DJ. New uses for old drugs. Nature, 2007, 448(7154): 645-646.
2. Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ, 2003, 22(2): 151-185.
3. Hay M, Thomas DW, Craighead JL, et al. Clinical development success rates for investigational drugs. Nat Biotechnol, 2014, 32(1): 40-51.
4. 盛苗苗, 蒋澄宇. 精确医学为老药新用及联合用药带来新契机. 生命科学, 2015, 27(3): 322-326.
5. Ekins S, Williams AJ. Finding promiscuous old drugs for new uses. Pharm Res, 2011, 28(8): 1785-1791.
6. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat product, 2012, 75(3): 311-335.
7. Cragg GM, Grothaus PG, Newman DJ. New horizons for old drugs and drug leads. J Nat Prod, 2014, 77(3): 703-723.
8. Li JW, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science, 2009, 325(5937): 161-165.
9. Sun Y, Liu Y, Chen K. Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives. Sci China Life Sci, 2016, 59(3): 292-298.
10. Smith I, Williamson EM, Putnam S, et al. Effects and mechanisms of ginseng and ginsenosides on cognition. Nutr Rev, 2014, 72(5): 319-333.
11. Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database Syst Rev, 2010, (12): CD007769.
12. Yang Z, Zhao T, Liu H, et al. Ginsenoside Rh2 inhibits hepatocellular carcinoma through β-catenin and autophagy. Sci Rep, 2016, 6: 19383.
13. Tian L, Shen D, Li X, et al. Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4. Oncotarget, 2016, 7(2): 1619.
14. Guo M, Liu Y, Shi D. Cardiovascular actions and therapeutic potential of tetramethylpyrazine (active component isolated from rhizoma chuanxiong): roles and mechanisms. Biomed Res Int, 2016, 2016: 2430329.
15. Hui L, Xue YA, Wei SH, et al. Protective effects of tetramethylpyrazine on cerebrovascular regulations in rats with chronic alcoholic encephalopathy. Biomed Environ Sci, 2015, 28(9): 691-695.
16. Kong X, Zhong M, Su X, et al. Tetramethylpyrazine promotes migration of neural precursor cells via activating the phosphatidylinositol 3-kinase pathway. Mol Neurobiol, 2016, 53(9): 6526-6539.
17. Wang C, Wang P, Zeng W, et al. Tetramethylpyrazine improves the recovery of spinal cord injury via Akt/Nrf2/HO-1 pathway. Bioorg Med Chem Lett, 2016, 26(4): 1287-1291.
18. Yin J, Zhang H, Ye J. Traditional Chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets, 2008, 8(2): 99-111.
19. Xia X, Yan J, Shen Y, et al. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6(2): e16556.
20. Tillhon M, Ortiz LM, Lombardi P, et al. Berberine: new perspectives for old remedies. Biochem Pharmacol, 2012, 84(10): 1260-1267.
21. Mahmood K, Zia KM, Zuber M. Recent developments in curcumin and curcumin based polymeric materials for biomedical applications: a review. Int J Biol Macromol, 2015, 81: 877-890.
22. Seo HJ, Wang SM, Han C, et al. Curcumin as a putative antidepressant. Expert Rev Neurother, 2015, 15(3): 269-280.
23. Kaufmann FN, Gazal M, Bastos CR, et al. Curcumin in depressive disorders: an overview of potential mechanisms, preclinical and clinical findings. Eur J Pharmacol, 2016, 784: 192-198.
24. Al-Karawi D, Mamoori A, Alem D, et al. The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother Res, 2016, 30(2): 175-183.
25. Ho WE, Peh HY, Chan TK, et al. Artemisinins: pharmacological actions beyond anti-malarial. Pharmacol Ther, 2014, 142(1): 126-139.
26. Jin O, Zhang H, Gu Z, et al. A pilot study of the therapeutic efficacy and mechanism of artesunate in the MRL/lpr murine model of systemic lupus erythematosus. Cell Mol Immunol, 2009, 6(6): 461.
27. Li J, Casteels T, Frogne T, et al. Artemisinins target GABAA receptor signaling and impair α cell identity. Cell, 2017, 168(1-2): 86-100, 115.
28. Liu J, Lee J, Salazar HMA, et al. Treatment of obesity with celastrol. Cell, 2015, 161(5): 999-1011.
29. 信琪琪, 刘玥, 杨琳, 等. 中药银杏制剂与糖尿病治疗: 作用机制与临床应用. 中国中药杂志, 2014, 39(23): 4509-4515.
30. Zhi Y, Pan JH, Shen WH, et al. Ginkgolide B inhibits human bladder cancer cell migration and invasion through MicroRNA-223-3p. Cell Physiol Biochem, 2016, 39(5): 1787-1794.
31. Xu K, Wang P, Xu X, et al. An overview on structural modifications of ligustrazine and biological evaluation of its synthetic derivatives. Res Chem Intermediat, 2015, 41(3): 1385-1411.
32. 刘瑞武, 尹大力, 郭积玉. 10 位结构修饰 14β-侧链紫杉醇衍生物的合成及其抗肿瘤活性. 中国药物化学杂志, 2000, 10(1): 18-25.
33. Li Q, Wang Y, Feng N, et al. Novel polymeric nanoparticles containing Tanshinone IIA for the treatment of hepatoma. J Drug Target, 2008, 16(10): 725-732.
34. 任瑾, 杜倩, 艾凤伟, 等. 药物新剂型与新技术在中药制剂中的应用开发. 中成药, 2015, 37(2): 392-396.
35. Li S. Farmework and practice of network based studies for Chinese herbal formula. J Chin Integr Med, 2007, 5(5): 489-493.
36. Hopkins AL. Network pharmacology. Nat Biotechnol, 2007, 25(10): 1110-1111.
37. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol, 2008, 4(11): 682-690.
38. 张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展. 中国药理学与毒理学杂志, 2015, 29(6): 883-892.
39. 张永祥, 程肖蕊, 周文霞. 药物重定位—网络药理学的重要应用领域. 中国药理学与毒理学杂志, 2012, 26(6): 779-786.
40. Yang H, Shen Y, Chen J, et al. Structure-based virtual screening for identification of novel 11β-HSD1 inhibitors. Eur J Med Chem, 2009, 44(3): 1167.
41. 梁英喜, 贺昱甦, 蒋芦荻, 等. 利用重定位策略从中药中发现 L-型钙离子通道作用降压药. 中国中药杂志, 2015, 40(18): 2650-2654.
42. 杨珍, 张燕玲, 乔延江. ETB 受体拮抗剂三维药效团的构建. 世界科学技术-中医药现代化, 2014, 14(4): 1786-1792.
43. 吴纯伟, 路丽, 梁生旺, 等. 药物靶标预测技术在中药网络药理学中的应用. 中国中药杂志, 2016, 41(3): 377-382.
44. Liang XJ, Li HY, Li S. A novel network pharmacology approach to analyse traditional: herbal formulae: the liu-wei-di-huang pill as a case study. Mol Bio Syst, 2014, 10(5): 943-1212.
45. Li HY, Zhao LH, Zhang B, et al. A network pharmacology approach to determine active compounds and action mechanisms of ge-gen-qin-lian decoction for treatment of type 2 diabetes. Evid Based Complement Alternat Med, 2014, 2014: 495840.
46. Liu HP, Zeng LT, Yang KL, et al. A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility. Evid Based Complement Alternat Med, 2016, 2016: 2960372.
47. 李翔, 吴磊宏, 范骁辉, 等. 复方丹参方主要活性成分网络药理学研究. 中国中药杂志, 2011, 36(21): 2912-2915.
48. Nielsen SK, Ursu O, Yang JJ, et al. Associating drugs, targets and clinical outcomes into an integrated network affords a new platform for computer-aided drug repurposing. Mol Inform, 2011, 30(2-3): 100-111.

Chinese Journal of Evidence-Based Medicine

Network pharmacology in drug repositioning of Chinese medicines: application status and thinking

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content